BI-765063 by Boehringer Ingelheim International for Hypopharyngeal Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BI-765063 overview

BI-765063 (OSE-172) is under development for the treatment of solid tumors including recurrent head and neck squamous cell carcinoma (HNSCC), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic colorectal cancer and hepatocellular carcinoma. The drug candidate is a second generation check point inhibitor. It acts by targeting cells expressing SIRP-alpha (Signal Regulatory Protein alpha) and CD47. It is administered through intravenous route. The drug candidate was also under development for mesothelioma, renal cell carcinoma, melanoma, non-small cell lung cancer, pancreatic cancer, head and neck squamous cell carcinoma, urothelial carcinoma, small cell lung cancer, gastric cancer, triple negative breast cancer and ovarian cancer.

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

For a complete picture of BI-765063’s drug-specific PTSR and LoA scores, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.